XEOMIN
(IncobotulinumtoxinA)Phase 3Small molecule
XEOMIN is a small molecule that works as a Synaptosomal Nerve-Associated Protein 25 (SNAP-25) Inhibitor.[2] It is being investigated across 6 indications, with its most advanced program in Phase 3.[1]
XEOMIN is one of 132 small molecule programs targeting Multiple Sclerosis. It is currently in Phase 3.
6
Indications
38
Total Trials
5
Active Trials
131
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
145 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1XEOMIN
MMerz Pharmaceuticals GmbH
Phase 3
Rinvoq
AbbViePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Zyrtec
KKenvue Brands
Phase 3
Frexalimab
SanofiPhase 3
Activated Charcoal
SanofiPhase 3
Antihistamine
Arrowhead PharmaceuticalsPhase 3
Recombinant Zoster Vaccine
MMAXVAX Biotechnology Limited Liability Company
Phase 3
Tolebrutinib
SanofiPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Glabellar Frown Lines5 trials
Spasticity5 trials
Cerebral Palsy3 trials
Tremor2 trials
19 more indications
Chronic Migraine2 trials
Cancer Pain1 trial
Injury1 trial
Restless Leg Syndrome1 trial
Rosacea1 trial
Concentration1 trial
Peripheral Neuropathy1 trial
Cervical Dystonia1 trial
Treatment1 trial
Episodic Migraine1 trial
Erectile Dysfunction1 trial
Primary Dysmenorrhea1 trial
Regulatory
FDA Approval Timeline[4]
Jul 30, 2010
XEOMIN
BLA BLA125360
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IncobotulinumtoxinA. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Synaptosomal Nerve-Associated Protein 25 (SNAP-25) Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMerz Pharmaceuticals GmbH